Wellington Management Group LLP Grows Position in Maze Therapeutics, Inc. $MAZE

Wellington Management Group LLP raised its holdings in Maze Therapeutics, Inc. (NASDAQ:MAZE) by 36.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 82,724 shares of the company’s stock after acquiring an additional 22,137 shares during the period. Wellington Management Group LLP’s holdings in Maze Therapeutics were worth $2,468,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in MAZE. Royal Bank of Canada grew its holdings in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Maze Therapeutics in the fourth quarter valued at $43,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth about $48,000. Finally, Russell Investments Group Ltd. lifted its position in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after buying an additional 1,725 shares during the last quarter.

Insider Buying and Selling at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total transaction of $907,031.29. Following the completion of the sale, the chief executive officer owned 18,151 shares in the company, valued at $477,189.79. This represents a 65.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the sale, the chief marketing officer owned 16,142 shares of the company’s stock, valued at $445,680.62. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 219,317 shares of company stock worth $5,989,040 over the last 90 days. Corporate insiders own 5.30% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on MAZE. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Finally, BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock opened at $24.82 on Friday. The business has a 50-day simple moving average of $28.33 and a 200-day simple moving average of $30.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics, Inc. has a one year low of $20.00 and a one year high of $53.65. The company has a market cap of $1.38 billion, a PE ratio of -9.85 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, equities research analysts forecast that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.